Chemistry and Metabolism

Amersham* Radiolabelling Services was acquired by Quotient Bioresearch from GE Healthcare in June 2009.  The acquisition of the leading global supplier of radiolabelling services further enhanced Quotient’s existing radiosynthesis business.

Quotient Bioresearch is now a leading provider of radiolabelled material for use in both pre-clinical and clinical metabolism studies for the pharmaceutical and agrochemical industries.

A wide range of metabolism studies utilising radiolabelled compounds are provided. The DMPK department has long standing expertise in supporting drug discovery and development programmes.

Radiolabelled compounds are essential for quantitative metabolite profiling and metabolite identification allowing full interpretation of the Human Metabolites in Safety Testing (MIST) Guidelines when comparing pre-clinical and clinical metabolism.

 Contact us for more information or to discuss your specific needs

DMPK - Drug Metabolism and Pharmacokinetics